Management of irritable bowel syndrome

Postgraduate Medical Journal

Volumn 79, Issue 929, 2003, Pages 154-158

  Gunn, M C ^a   Cavin, A A ^a   Mansfield, John C ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ALVERINE CITRATE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BULKING AGENT; CISAPRIDE; CODEINE; COLESTYRAMINE; DICYCLOVERINE; DIPHENOXYLATE; DOMPERIDONE; ISPAGULA; LAXATIVE; LOPERAMIDE; MEBEVERINE; METOCLOPRAMIDE; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; ONDANSETRON; PEPPERMINT OIL; POLYCARBOPHIL CALCIUM; PROKINETIC AGENT; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANTICHOLINERGIC EFFECT; CONSTIPATION; DIARRHEA; DRUG DEPENDENCE; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; LONG QT SYNDROME; NAUSEA; PATHOGENESIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; VOMITING;

ANTIDEPRESSIVE AGENTS; COLONIC DISEASES, FUNCTIONAL; DIARRHEA; HUMANS; LIFE STYLE; SEROTONIN ANTAGONISTS; SOCIOECONOMIC FACTORS;

EID: 0242416658     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.929.154     Document Type: Review

References (56)

1. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002;360:555-64.
2. Thompson WG. Review article: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1395-406.
3. Camilleri M, Heading RC, Thompson WG. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1407-30.
4. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001;120:652-68.
5. Jones J, Boorman J, Cann P, et al. British Society of Gastraenterology guidelines for the management of the irritable bowel syndrome. Gut 2000;47(suppl 2):ii1-19.
6. Drossman DA, Corazziari E, Talley NJ, et al. Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut 1999;45(suppl 11):1-81.
7. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ 1978;ii:653-4.
8. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997;112:2120-37.
9. Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors and health care utilisation. Am J Epidemiol 1995;142:76-83.
10. Talley NJ, O'Keefe EA, Zinsmeister AR, et al. Prevalence of gastrointestinal symptoms in the elderly: a population based study. Gastroenterology 1992;102:895-901.
11. Jones R, Lydreard S. Irritable bowel syndrome in the general population. BMJ 1992;304:87-90.
12. Heaton KW, O'Donnell LJ, Braddon FE, et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992;102:1962-7.
13. Thompson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gastroenterology International 1992;5:75-91.
14. Lonstreth GF, Preskill DB, Youkeles L. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynaecological features and outcome. Dig Dis Sci 1990;35:1285-90.
15. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736-41.
16. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome reappraised with strategies to control expenditure. Pharmacoeconomics 2000;4:331-8.
17. Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990;34:483-91.
18. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993;38:1569-80.
19. Delvaux M, Denis P, Allemand H. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive disease or controls. Results of a multicentre inquiry. Eur J Gastroenterol Hepatol 1997;9:345-52.
20. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113:828-33.
21. Whitehead WE, Winget C, Fedoravicius AS, et al. Leorned illness behavior in patients with irritable bowel syndrome and peptic ulcer. Dig Dis Sci 1982;27:202-8.
22. Van Der Horst HE, Van Dulmen AM. Do patients with irritable bowel syndrome in primary care really differ from outpatients with irritable bowel. Gut 1997;42:669-74.
23. Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994;106:945-50.
24. harucha AE, Camilleri M, Low PA, et al. Autonomic dysfunction in gastrointestinal motility disorders. Gut 1993;34:397-401.
25. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973;14:125-32.
26. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98(5 pt 1):1187-92.
27. Gwee KA, Graham JC, Mckendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996;347:150-3.
28. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400-6.
29. Neal KR, Hedben J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-82.
30. Jones VA, Mclaughlan P, Shorthouse M, et al. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982;ii:1115-7.
31. Nanda R, James R, Smith H, et al. Food intolerance and the irritable bowel syndrome. Gut 1989;30:1098-104.
32. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or hydrolysed milk by people with self reported severe lactose intolerance. N Engl J Med 1995;333:1-4.
33. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002;122:1701-4.
34. Francis CY, Duffy JN, Whorwell PJ, et al. Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome? Am J Gastroenterol 1996;91:1348-50.
35. Macintosh DG, Thompson WG, Patel DG, et al. Is rectal biopsy necessary in irritable bowel syndrome? Am J Gastroenterol 1992;87:1407-9.
36. Thompson WG, Heaton KW, Smyth GT, et al. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol 1997;9:689-92.
37. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling Rome II criteria referred to secondary care. Lancet 2001;358:1504-8.
38. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long term prognosis and the physician-patient interaction. Ann Intern Med 1995;122:107-12.
39. Lynch PM, Zamble E. A controlled behavioural treatment study of irritable bowel syndrome. Behav Ther 1989;20:509-23.
40. Neff DF, Blanchard EB. A multi-component treatment for irritable bowel syndrome. Behav Ther 1987;18:70-83
41. Talley NJ, Owen BK, Boyce P, et al. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-83.
42. Whorell PJ. Hypnotherapy in the irritable bowel syndrome. Stress Medicine 1987;3:5-7.
43. Payne A, Blanchard EB. Controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J Consult Clin Psychol 1995;63:779-86.
44. Farthing MJG. Fortnightly review: irritable bowel, irritable body, or irritable brain? BMJ 1995;310:171-5.
45. Farthing MJG. New drugs in the management of the irritable bowel syndrome. Drugs 1998;56:11-21.
46. Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984;25:168-73.
47. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994;344:39-40.
48. Jaiwala J, Imperiale TF, Kroenke K. Pharmacologic: treatment of the irritable bowel syndrome: a systematic review of randomised, controlled trials. Ann Intern Med 2000;133:136-45.
49. Mitchell SA, Mee AS, Smith GD, et al. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther 2002;16:1187-95.
50. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988;95:232-41.
51. Williams AK, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption. A review of clinical presentation, diagnosis and response to treatment. Gut 1991;32:1004-6.
52. De Panti F, Tonini M. Irritable bowel syndrome. New agents targeting serotonin receptor subtypes. Drugs 2001;61:317-32.
53. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
54. 4 receptor partial agonist, accelerates gastric emplying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-51.
55. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastronterology 2001;120:354-60.
56. Otten M, Schneider H, Wurzer H, et al. A double blind, placebo controlled evaluation of safely and efficacy of 12 week, twice daily treatment with prucalopride in patients with chronic constipation. Gastroenterology 1999;116:1055.